The present invention provides a compound of formula I wherein Y is N or C—R1 ′； G is selected from the group consisting of halogen, lower alkyl, lower alkoxy, lower alkoxy substituted by halogen or NRR ′ Selected from the group consisting of phenyl, pyridinyl with different N positions, imidazolyl, pyrazinyl, pyrimidinyl, thiophenyl, thiazolyl, pyrazolyl or thiadiazolyl, optionally substituted by 1, 2 or 3 substituents, A 5- or 6-membered aromatic or aromatic heterocycle containing 1, 2 or 3 heteroatoms； R and R ′ are independently of each other hydrogen or lower alkyl, or they are bonded 5- or 6-membered saturated heterocyclic groups which may contain additional oxygen, NH or N-lower alkyl groups together with the N atom R1 is hydrogen, halogen, or lower alkyl substituted by halogen； R1 ′ is hydrogen, halogen, or lower alkyl substituted by halogen； R2 is hydrogen, Lower alkyl, lower alkoxyalkyl, cycloalkyl or heterocycloalkyl； or R2 together with the nearest carbon atom in group G is a group (IA) (where A is -CH2-, -CH2CH2, or -C (CH3) 2-, and R3 is phenyl or pyridinyl, wherein the N atoms in the pyridinyl group may be in different positions.] To the indicated compound, or to a pharmaceutically acceptable salt or acid addition salt thereof, to a racemic mixture, or to the corresponding enantiomer and / or optical derivative thereof. Body and / or stereoisomer thereof relates. Surprisingly, the compounds of general formula I are metabotropic glutamate receptors useful for the treatment of Parkinson's disease, anxiety, vomiting, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and type 2 diabetes. It was found to be a positive allosteric modulator (PAM) of body 4 (mGluR4).本発明は、式Ｉ［式中、Ｙは、Ｎ又はＣ－Ｒ１’であり；Ｇは、ハロゲン、低級アルキル、低級アルコキシ、ハロゲンによって置換されている低級アルコキシ又はＮＲＲ’からなる群より選択される１、２又は３個の置換基によって場合により置換されている、フェニル、異なるＮ位置を有するピリジニル、イミダゾリル、ピラジニル、ピリミジニル、チオフェニル、チアゾリル、ピラゾリル又はチアジアゾリルからなる群より選択される、０、１、２又は３個のヘテロ原子を含有する５又は６員の芳香環又は芳香族複素環であり；Ｒ及びＲ’は、互いに独立して、水素もしくは低級アルキルであるか、又は
